|
Report Date : |
17.08.2012 |
IDENTIFICATION DETAILS
|
Name : |
QUALICAPS CO LTD |
|
|
|
|
Registered Office : |
321-5 Ikezawacho
Yamatokoriyama Nara City 639-1032 |
|
|
|
|
Country : |
Japan |
|
|
|
|
Financials (as on) : |
31.12.2011 |
|
|
|
|
Date of Incorporation : |
April
1965 |
|
|
|
|
Com. Reg. No.: |
(Nara-Yamatokoriyama) 005846 |
|
|
|
|
Legal Form : |
Limited Company |
|
|
|
|
Line of Business : |
Manufacturer of capsules, capsule filling & sealing
equipment |
|
|
|
|
No. of Employees : |
204 employees |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2012
|
Country Name |
Previous Rating (31.12.2011) |
Current Rating (31.03.2012) |
|
Japan |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
QUALICAPS CO LTD
Qualicaps KK
321-5 Ikezawacho
Yamatokoriyama Nara City 639-1032 JAPAN
Tel:
0473-56-0651 Fax: 0743-56-6666
URL: http://www.qualicaps.co.jp
E-Mail address: contact@qualicaps.co.jp
Mfg of
capsules, capsule filling & sealing equipment
Nil
At the
caption address
Qualicaps
Inc (USA); Qualicaps Europe SA (Spain) (--subsidiaries)
TAKAYUKI
KAWAMURA, PRES Tamotsu Adachi,
dir
Masao
Hirano, dir Takaomi
Tomioka, dir
Koji
Tanabe, auditor
Yen
Amount: In million Yen, unless
otherwise stated
FINANCES FAIR A/SALES Yen
68,147 M
PAYMENTS No
Complaints CAPITAL Yen 2,833 M
TREND UP WORTH Yen 10,503 M
STARTED 1965 EMPLOYES 204
MFR OF GELATIN CAPSULES, CAPSULE FILLING MACHINED, OWNED BY
CARLYLE GROUP, PRIVATE EQUITY FIRM.
FINANCIAL SITUATION CONSIDERED FAIR AND GOOD FOR ORDINARY
BUSINESS ENGAGEMENTS.
The subject company was established originally as JV between Eli Lilly (USA) and Shionogi & Co Ltd, major antibiotics mfr, Osaka, for advancing into mfg gelatin capsules and capsule filling machines for the pharmaceutical & dietary supplement industries. In Dec 2005, Singe’s stocks were bought by Carlyle Group’s private equity firm, USA by means of MBO and its name was deleted from the corporate title and became independent as Qualicaps Co Ltd. The firm specializes in mfg hard gelatin capsules, HPMC capsules, capsule filling & sealing equipment. Two overseas subsidiaries in USA and Spain are also engaged in mfg of these capsules. They are imported, too.
The firm stopped releasing full financials as from the 31/12/2007 fiscal term and only partial figures are disclosed.
The sales volume for Dec/2011 fiscal term amounted to Yen 8,147 million, a 29% up from Yen 6,317 million in the previous term. The recurring profit was posted at 1,286 million and the net profit at Yen 570 million, respectively, compared with Yen 384 million net profit a year ago.
For the current term ending Dec 2012 the net profit is projected at Yen 600 million, on a 3% rise in turnover, to Yen 8,400 million.
The financial situation is considered FAIR and good for ORDINARY business engagements.
Date Registered: Apr 1965
Regd No.: (Nara-Yamatokoriyama) 005846
Legal Status: Limited
Company (Kabushiki Kaisha)
Authorized:
56,600 shares
Issued:
56,600 shares
Sum: Yen 2,830 million
*
Increased the capital in 2008.
Major shareholders (%): Carlyle Group*(100)
*.. Private equity finance firm,
USA with its office in Tokyo
Nothing detrimental is known as
to the commercial morality of executives.
Activities: Manufactures hard gelatin capsules, HPMC capsules, capsule filling & sealing equipment, other related supplies (--100%).
Clients: [Pharmaceutical mfrs, dietary supplement mfrs] Eisai Co, Shionogi & Co, Tanabe Seiyaku, Takeda Pharmaceutical, Dainippon Sumitomo Pharma, Chugai Pharmaceutical, Ono Pharmaceutical, Astellas Pharma, Sato Yakuhin Kogyo, FNCL,
other.
No. of accounts: 1,000
Domestic areas of activities: Nationwide
Suppliers: [Mfrs, wholesalers] Eisai Co, Takeda Pharmaceutical, Nitta Gelatin,
Shin-Etsu Chemical Ind, Rousselot Japan, Yamamoto Seiko, Eisai Machinery, Ono
Pharmaceuticals, other.
Payment record: No Complaints
Location: Business area in Yamatokoriyama City, Nara-Pref. Office premises at the caption address are owned and maintained satisfactorily.
Bank References:
JP
Morgan Bank (Tokyo)
SMBC
(Osaka)
Relations:
Satisfactory
(In Million Yen)
|
|
|
31/12/2012 |
31/12/2011 |
31/12/2010 |
31/12/2009 |
|
Annual
Sales |
|
8,400 |
8,147 |
6,317 |
6,484 |
|
Recur.
Profit |
|
|
1,286 |
|
|
|
Net
Profit |
|
600 |
570 |
384 |
-223 |
|
Total
Assets |
|
|
22,396 |
N/A |
N/A |
|
Net
Worth |
|
|
10,503 |
9,934 |
9,550 |
|
Capital,
Paid-Up |
|
|
2,833 |
2,833 |
2,833 |
|
Div.P.Share(¥) |
|
|
0.00 |
0.00 |
0.00 |
|
<Analytical Data> |
(%) |
(%) |
(%) |
(%) |
|
|
S.Growth Rate |
3.11 |
28.97 |
-2.58 |
-7.15 |
|
|
Current Ratio |
|
|
|
.. |
.. |
|
N.Worth Ratio |
|
46.90 |
.. |
.. |
|
|
N.Profit/Sales |
7.14 |
7.00 |
6.08 |
-3.44 |
|
Note:
Financials are only partially disclosed as from the 31/12/2007 fiscal term.
Forecast
(or estimated) for the 31/12/2012 fiscal term.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.55.98 |
|
UK Pound |
1 |
Rs.87.55 |
|
Euro |
1 |
Rs.68.69 |
INFORMATION DETAILS
|
Report Prepared
by : |
MNL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.